ArticleHeliyon2025
Black posterior vitreous detachment: A 10-year historical cohort of pigmented uveal tumors.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pigmentary posterior vitreous detachment (PVD), referred to as "black PVD," is a rare entity describing PVD along with pigment dispersion in the vitreous. There are a few case reports describing pigmentary PVD, yet the association between pigmentary PVD and uveal and optic disc tumors was not described before. The aim of this study was to report the clinical features of patients with pigmentary PVD associated with these tumors. Design: An 8-year retrospective cohort study. Participants: Eight patients who were diagnosed with pigmentary PVD associated with a uveal tumor or optic nerve pigmented tumors in a tertiary medical center. Methods: Demographics, clinical data, type of uveal lesion, treatment, multimodal images, and follow-up information were retrieved.The main outcome measures were tumor recurrence, vitreous spread, and the patient's prognosis. Results: Most patients were female (5/8; 62.5 %), with a mean age of 55.8 ± 4.41 years. The right eye was more frequently involved (5/8; 62.5 %). The most prevalently associated ocular tumor was malignant choroidal melanoma (7/8; 87.5 %). A pigmentary PVD was observed on presentation in one case (1/8; 12.5 %); the remaining cases had pigmentary PVD documented during follow-up. VA was significantly worse at the end of follow-up, with a mean of 0.10 ± 0.14 logMAR at the first appointment and 1.20 ± 0.37 logMAR at the last appointment (p = 0.0101). The IOP remained stable, with a mean of 13.5 ± 0.63 mmHg at the first appointment and 14.5 ± 0.50 mmHg at the last appointment (p = 0.2328). The median follow-up duration was 63.5 months. Patients presented with a mean initial lesion thickness of 4.8 ± 1.01 mm, which remained stable throughout the follow-up with a mean thickness of 3.2 ± 0.71 (p = 0.2173). None of the cases exhibited recurrence, vitreous spread, or growth of the ocular lesion during follow-up. Conclusion: A pigmentary form of PVD may accompany both benign and malignant pigmented uveal tumors, affecting a wide range of patients. The dispersion of pigment from the tumor collars the vitreous in black, yet the black PVD does not necessarily indicate tumor recurrence or vitreous spread.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.